270 related articles for article (PubMed ID: 31415087)
1. Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial.
Depypere H; Timmerman D; Donders G; Sieprath P; Ramael S; Combalbert J; Hoveyda HR; Fraser GL
J Clin Endocrinol Metab; 2019 Dec; 104(12):5893-5905. PubMed ID: 31415087
[TBL] [Abstract][Full Text] [Related]
2. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.
Fraser GL; Lederman S; Waldbaum A; Kroll R; Santoro N; Lee M; Skillern L; Ramael S
Menopause; 2020 Apr; 27(4):382-392. PubMed ID: 32102086
[TBL] [Abstract][Full Text] [Related]
3. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA).
Santoro N; Waldbaum A; Lederman S; Kroll R; Fraser GL; Lademacher C; Skillern L; Young J; Ramael S
Menopause; 2020 Dec; 27(12):1350-1356. PubMed ID: 32769757
[TBL] [Abstract][Full Text] [Related]
4. Systematic review of neurokinin-3 receptor antagonists for the management of vasomotor symptoms of menopause.
Cieri-Hutcherson NE; Marji EK; Hutcherson TC
Menopause; 2024 Apr; 31(4):342-354. PubMed ID: 38471077
[TBL] [Abstract][Full Text] [Related]
5. Fezolinetant in the treatment of vasomotor symptoms associated with menopause.
Depypere H; Lademacher C; Siddiqui E; Fraser GL
Expert Opin Investig Drugs; 2021 Jul; 30(7):681-694. PubMed ID: 33724119
[No Abstract] [Full Text] [Related]
6. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
Lederman S; Ottery FD; Cano A; Santoro N; Shapiro M; Stute P; Thurston RC; English M; Franklin C; Lee M; Neal-Perry G
Lancet; 2023 Apr; 401(10382):1091-1102. PubMed ID: 36924778
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of fezolinetant in alleviating vasomotor symptoms linked to Menopause.: A systematic review and Meta-Analysis.
Elnaga AAA; Alsaied MA; Elettreby AM; Ramadan A
Eur J Obstet Gynecol Reprod Biol; 2024 Jun; 297():142-152. PubMed ID: 38640780
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I).
Ruan X; Bai W; Ren M; Kim T; Lee JY; Chuang FC; Wang PH; He W; Ma X; Miyazaki K; Song N; Wang X; Yu Q
J Int Med Res; 2024 May; 52(5):3000605241247684. PubMed ID: 38818888
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.
Johnson KA; Martin N; Nappi RE; Neal-Perry G; Shapiro M; Stute P; Thurston RC; Wolfman W; English M; Franklin C; Lee M; Santoro N
J Clin Endocrinol Metab; 2023 Jul; 108(8):1981-1997. PubMed ID: 36734148
[TBL] [Abstract][Full Text] [Related]
10. Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome.
Fraser GL; Obermayer-Pietsch B; Laven J; Griesinger G; Pintiaux A; Timmerman D; Fauser BCJM; Lademacher C; Combalbert J; Hoveyda HR; Ramael S
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3519-e3532. PubMed ID: 34000049
[TBL] [Abstract][Full Text] [Related]
11. Menopausal symptom management: Fezolinetant's varied doses provide effective relief for vasomotor symptoms in women - A meta-analysis of 3291 participants.
Elhusein AM; Fadlalmola HA; Abedelwahed HH; Elshaikh AA; Banaga AE; Alrahman MHF; Abdelgadim NH; Mohammed IH; Abdalla AAA; Abdalla FAM; Abd Allah EM; Abbas NI; Alhujaili AD; Almkiy EA; Idress EA; Awadalkareem EM; Abdeldafie SY; Balusamy P; Mohamed RA; Aloufi RSM; Habiballa M; Abdelmalik MA; Alhejaili MM; Ibrahim IA; Masaad HK
Afr J Reprod Health; 2024 Mar; 28(3):99-113. PubMed ID: 38583073
[TBL] [Abstract][Full Text] [Related]
12. Effects of neurokinin 3 receptor antagonist fezolinetant on hot flash-like symptoms in ovariectomized rats.
Tahara A; Takamatsu H; Ohtake A; Tanaka-Amino K; Kaku S
Eur J Pharmacol; 2021 Aug; 905():174207. PubMed ID: 34048742
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety of fezolinetant in Chinese women with vasomotor symptoms associated with menopause: the phase 3 open-label MOONLIGHT 3 clinical trial.
Yu Q; Ming F; Ma J; Cai Y; Wang L; Ren M; Zhang J; Ma X; Miyazaki K; He W; Wang X
J Int Med Res; 2024 May; 52(5):3000605241246624. PubMed ID: 38818887
[TBL] [Abstract][Full Text] [Related]
14. Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2).
Santoro N; Nappi RE; Neal-Perry G; English M; King DD; Yamaguchi Y; Ottery FD
Menopause; 2024 Apr; 31(4):247-257. PubMed ID: 38517210
[TBL] [Abstract][Full Text] [Related]
15. Fezolinetant for the treatment of vasomotor symptoms associated with menopause: a meta-analysis.
Chavez MP; Pasqualotto E; Ferreira ROM; Hohl A; de Moraes FCA; Schmidt PHS; Rodrigues ALSO; de Sa JR
Climacteric; 2024 Jun; 27(3):245-254. PubMed ID: 38619017
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Fezolinetant for the Treatment of Menopause-Associated Vasomotor Symptoms: A Meta-analysis.
Bonga KN; Mishra A; Maiti R; Padhy BM; Meher BR; Srinivasan A
Obstet Gynecol; 2024 Mar; 143(3):393-402. PubMed ID: 38227939
[TBL] [Abstract][Full Text] [Related]
17. Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.
Morga A; Ajmera M; Gao E; Patterson-Lomba O; Zhao A; Mancuso S; Siddiqui E; Kagan R
Menopause; 2024 Jan; 31(1):68-76. PubMed ID: 38016166
[TBL] [Abstract][Full Text] [Related]
18. Fezolinetant: First Approval.
Lee A
Drugs; 2023 Aug; 83(12):1137-1141. PubMed ID: 37462862
[TBL] [Abstract][Full Text] [Related]
19. Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2).
Nappi RE; Johnson KA; Stute P; Blogg M; English M; Morga A; Scrine L; Siddiqui E; Ottery FD
Menopause; 2024 Jun; 31(6):512-521. PubMed ID: 38626380
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of fezolinetant, a neurokinin-3 antagonist, in treating vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis.
Rahman UA; Kashif TB; Usman M; Rana M; Hasanain M; Anjum MU; Cheema HA; Jaffar H; Bhattarai P
Medicine (Baltimore); 2023 Dec; 102(50):e36592. PubMed ID: 38115258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]